Recurrent BEND2 Fusion Genes Identified by Whole Transcriptome Sequencing of Nonfunctional Pancreatic Neuroendocrine Tumors Correlate With Poor Patient Prognosis
Modern Pathology · 2025
DOI: 10.1016/j.modpat.2025.100863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2025. Verfasst von Michelle A Wood-Trageser und 55 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Biomarkers, Tumor, Neuroendocrine Tumors, Gene Fusion. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Neuroendocrine Tumor Research Foundation, National Cancer Institute.
Abstract (Originalsprache)
Pancreatic neuroendocrine tumors (PanNETs) exhibit heterogeneous clinical behavior, and a growing number of nonfunctional PanNETs (NF-PanNETs) have been discovered incidentally. Although chromatin remodeling and telomere maintenance gene alterations, such as ATRX and DAXX mutations, are well established in the metastatic progression of PanNETs, many tumors lack known driver mutations. To identify additional prognostic biomarkers and alternative oncogenic mechanisms in primary NF-PanNETs, we employed whole transcriptome sequencing on 73 nonsyndromic NF-PanNETs with extended clinical follow-up (>4 years). Findings were validated via immunohistochemistry in an independent multi-institutional cohort of 539 PanNETs. Clinicopathologic correlation and survival analyses assessed the prognostic significance of identified biomarkers. Transcriptomic profiling identified 6 distinct clusters, with cluster 6 (C6) demonstrating aggressive features, including high World Health Organization grade and distant metastases. Gene ontology pathway analysis of C6 tumors revealed upregulation of protein homeostasis, immune regulation, insulin metabolic activity, and telomere maintenance via telomerase activation. Recurrent fusion genes involving the chromatin remodeling gene, BEND2 (CHD7::BEND2 and EWSR1::BEND2), were detected in 7% (5/73) of NF-PanNETs, exclusively in C6 and independent of ATRX/DAXX status. Orthogonal validation showed BEND2 expression in 3% (16/539) of PanNETs, all harboring BEND2 fusion genes by whole transcriptome sequencing. Patients with BEND2-positive tumors had significantly shorter disease-free survival (P < .001) and disease-specific survival (P < .001). Furthermore, multivariate analysis confirmed BEND2 as an independent negative prognostic factor for disease-free survival (P < .001) and disease-specific survival (P = .001). Overall, ATRX, DAXX, and BEND2 alterations were present in 62% of metastatic NF-PanNETs. This study identifies recurrent BEND2 fusion genes as a novel oncogenic mechanism in aggressive NF-PanNETs and establishes BEND2 expression as an independent prognostic biomarker, emphasizing the importance of chromatin remodeling and telomere maintenance in the metastatic progression of NF-PanNETs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
- Department of Pathology, University Medical Center Utrecht, Utrecht University, The Netherlands.
- Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Förderung
- NCI NIH HHS
- Neuroendocrine Tumor Research Foundation
- National Cancer Institute
- National Institutes of Health
- University of Pittsburgh
- Sky Foundation
- National Pancreas Foundation
- Olympus
Zitieren
APA
Wood-Trageser, M. A., Nichols, C. T., Hutchings, D. A., Bell, D., Wald, A. I., Smith, K., Hong, S. M., Luchini, C., Brosens, L. A. A., Verschuur, A. V. D., Bevere, M., Lawlor, R. T., Scarpa, A., Keating, S., Tucker, J., O'Sullivan, R. J., Liu, T. C., McGrath, K., Fasanella, K., …, & Singhi, A. D. (2025). Recurrent BEND2 Fusion Genes Identified by Whole Transcriptome Sequencing of Nonfunctional Pancreatic Neuroendocrine Tumors Correlate With Poor Patient Prognosis. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100863
Vancouver
Wood-Trageser MA, Nichols CT, Hutchings DA, Bell D, Wald AI, Smith K, et al. Recurrent BEND2 Fusion Genes Identified by Whole Transcriptome Sequencing of Nonfunctional Pancreatic Neuroendocrine Tumors Correlate With Poor Patient Prognosis. Modern Pathology. 2025. doi:10.1016/j.modpat.2025.100863
BibTeX
@article{WoodTrageser2025,
author = {Wood-Trageser, Michelle A and Nichols, C Tolson and Hutchings, Danielle A and Bell, Diana and Wald, Abigail I and Smith, Katelyn and Hong, Seung-Mo and Luchini, Claudio and Brosens, Lodewijk A A and Verschuur, Anna Vera D and Bevere, Michele and Lawlor, Rita T and Scarpa, Aldo and Keating, Shannon and Tucker, James and O'Sullivan, Roderick J and Liu, Ta-Chiang and McGrath, Kevin and Fasanella, Kenneth and Brand, Randall E and Lennon, Anne Marie and Das, Rohit and Singh, Harkirat and Slivka, Adam and Mahmood, Sultan and Hosmer, Amy E and Khalid, Asif and Romutis, Stephanie L and Zureikat, Amer H and Zeh, Herbert J and Hogg, Melissa E and Lee, Kenneth K and Paniccia, Alessandro and Nunns, Geoffrey and Ongchin, Melanie and Park, Walter G and Polanco, Patricio M and He, Jin and Simeone, Diane M and Ferrone, Cristina R and Hsu, Dennis and Zhang, Janie and Gorantla, Vikram and Rhee, John and Hruban, Ralph H and Singhi, Anju H and Singhi, Sara A and Wang, Candice K and Shaker, Nuha and Bubar, Robert and Grupillo, Maria and Lai, Yi-Tak and Nikiforova, Marina N and Heaphy, Christopher M and Waters, Kevin M and Singhi, Aatur D},
title = {Recurrent BEND2 Fusion Genes Identified by Whole Transcriptome Sequencing of Nonfunctional Pancreatic Neuroendocrine Tumors Correlate With Poor Patient Prognosis},
journal = {Modern Pathology},
year = {2025},
doi = {10.1016/j.modpat.2025.100863}
}
EUVIMED